FeesSafety
Pluang+

Hyperliquid Strategies DAT denies buying 3.75M HYPE in $320M OTC deal from Hyperliquid Labs

Market News
08 Oct 2026, 04:18 WIB
Tokenpost
View Source
Neutral
Hyperliquid Strategies DAT denies buying 3.75M HYPE in $320M OTC deal from Hyperliquid Labs

Hyperliquid Strategies DAT (PURR) CEO David Schamis denied that his company purchased 3.75 million HYPE tokens from Hyperliquid Labs in an over-the-counter transaction valued at around $320 million. Hyperliquid Labs sold 3.75 million HYPE tokens via OTC, with part transferred to five buyer wallets and part restaked. The denial from PURR separates the buyer's identity from the company's treasury, leaving the actual buyer(s) unknown. This matters because of the transaction's large size and its connection to a company holding HYPE tokens.

The PURR CEO's denial of receiving 3.75 million HYPE tokens is presented with Pluang's cryptocurrency market data as of Oct 08, 2026 08:21 WIB. For readers following major cryptocurrencies on Pluang, 7 out of 50 rose while 42 fell. Notable movers include CRV (Curve DAO Token) rising 7.60% to Rp6.981, FIL (Filecoin) falling 7.70% to Rp19.207, and EGLD (MultiversX) dropping 7.10% to Rp73.993, with EGLD showing 100% buy order activity.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
49 minutes ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
58 minutes ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App